Seòmar agus comataidhean

I refer the member to the answer to question S5W-11009 on‎ 30 September 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

The Scottish Government is committed to the recruitment of a minimum of 1,500 additional staff to support the operation of Scotland’s National Treatment Centres (NTCs) and is supporting a range of activity to achieve this.

The recruitment data we are currently collating is management information and not suitable for publication. However, we are committed to exploring how this data can be published at a future date following with the opening of Centres in Fife and Forth Valley in early 2023.

£10 million of funding has been directed to support Cancer Waiting Times improvements in our NHS across 2022-23. Significant funds are going towards up-skilling nurses and investing in diagnostic tests to support extended working days/weekend working to increase capacity.

Meanwhile, work is underway to develop Scotland’s new cancer strategy, expected to publish Spring 2023. A recent public consultation received over 250 responses, including from blood cancer charities. A series of workshops are planned throughout September to help gain further insight and hear directly from those with lived experience to inform the focus of this strategy.

The Scottish Funding Council (SFC) collects and analyses data relating to the provision of further and higher education in Scotland. Table 1 below highlights data from SFC showing both the recommended and actual intakes to pre-registration nursing and midwifery programmes, broken down by year from 2019-20, 2020-21 and 2021-22. Nursing and Midwifery at the Open University in Scotland (OUiS) were funded through the SFC for the first time in 2021-22. As such figures for the SFC Early Statistics Collection are only available in 2021-22 and have been provided separately in Table 2.

Table 1

NHS Boards received notification on the 11 August of their share of the £50 million investment which has been allocated in its entirety to support NHS Health Boards to improve A&E waits through a new National Collaborative for Urgent and Unscheduled Care.

Each board’s share of the £50 million fund is listed below:

Rapid Cancer Diagnostic Services (RCDS) – formerly known as Early Cancer Diagnostic Centres (ECDC) – are fast-track diagnostic pathways taking patients from referral to diagnosis, not treatment.

Scotland’s first three RCDS are early adopters to help inform wider roll-out of an optimal model for patients with non-specific symptoms suspicious of cancer.

All three Services are using a nationally agreed minimum data-set, capturing consistent data from age, gender, symptoms at presentation etc. A sub-section of this data will be published by the three Boards in 2022.

Meanwhile, work is underway with Public Health Scotland to scope and progress national data collection as more sites are expected to be established.

The Scottish Government remains committed to supporting and growing our nursing and midwifery workforce. That is why student nurses and midwives entering Scottish Government funded degree programmes will increase by 8.7% in 2022-23, to a total recommended target intake of 4837 nursing and midwifery students.

Universities are continuing their recruitment for programmes commencing in the 2022-23 academic year. Final data on the number of placed applicants on nursing and midwifery programmes commencing in the 2022-23 academic year will not be available until January 2023.

Three Rapid Cancer Diagnostic Services (RCDS) – formerly known as Early Cancer Diagnostic Centres (ECDC) – have been opened in NHS Ayrshire and Arran, NHS Dumfries and Galloway and NHS Fife. An interim report on the rollout of RCDC's is expected shortly and are actively considering further rollout of Rapid Cancer Diagnostic Services.

All Boards have recruited both medical and non-medical staff to manage the new referral pathway for patients with non-specific symptoms, including navigators who support patients from the point of referral.

Recruitment for clinical services is the responsibility of individual Boards and it is therefore for them to provide specific details.

The University of Strathclyde has been commissioned to undertake critical evaluation of early adopter sites to inform wider roll-out, ensuring learnings from the first three Services are embedded, working towards equitable access across NHS Scotland, as set out in the NHS Recovery Plan.

In the meantime, officials are working with Boards to open additional early adopter sites.

Recruitment will be undertaken by the host Board, and will be dependent on their locally agreed pathway and resourcing requirements.

Throughout the pandemic, a UK-wide approach to the procurement of therapeutics has been vital to allow the UK to have the buying power to secure significant numbers of therapeutics in a competitive global market. This approach has ensured patients across the UK have had equal access to safe and effective medicines.

Evusheld ® was developed and tested before the emergence of the Omicron variant, and the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) conditional marketing authorisation outlined some remaining questions, including how effective Evusheld ® is against Omicron and the duration of its effect against current circulating variants. As a result, there is currently no established supply arrangement for Evusheld ® in the UK. The UK Health Security Agency (UKHSA) is carrying out further testing on the effectiveness of Evusheld ® against the Omicron variants which involve “live virus” tests taking place in the lab (“in vitro”). These tests are important because they provide certainty of the effectiveness of Evusheld ® against circulating variants and avoid the risk of introducing new variants through viral mutations.

The Scottish Government continues to closely monitor the outcome of further research to ensure that any decisions to make Evusheld ® available to patients in Scotland in the future are based on the best available evidence.